Market Chatter: ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial
South Korean biotechnology firm ABL Bio Inc. (KOSDAQ:298380) and its US-based partner I-MAB Biopharma entered a collaboration and supply agreement with New York-based pharmaceutical company Bristol-My
While Private Equity Firms Own 21% of I-Mab (NASDAQ:IMAB), Retail Investors Are Its Largest Shareholders With 59% Ownership
I-mab has appointed Dr. Phillip Dennis as its Chief Medical Officer.
On June 6th, Gelonghui announced that i-Mab appointed Dr. Phillip Dennis as Chief Medical Officer. Dr. Phillip Dennis will join i-Mab on June 17, 2024, leading global clinical development and serving as a member of i-Mab's executive leadership team. "I am delighted to welcome Dr. Phillip Dennis as our Chief Medical Officer. Dr. Phillip Dennis has extensive experience in oncology drug development.
Express News | I-Mab Appoints Phillip Dennis, Md, Phd, as Chief Medical Officer
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of high
Bristol Myers Squibb Inks Clinical Trial Pact With I-Mab
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million. Concord Medical Services (NYSE:CCM) s
I-mab (IMAB.US) will work with Bristol Myers Squibb to evaluate the combination use of Givastomig in stomach and esophageal cancers.
On June 5th, Gallant announced that on June 5th, 2024, the company signed a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY). The collaboration will evaluate Givastomig (a Claudin18.2x4-1BB bispecific antibody developed by I-Mab and ABL Bio (KOSDAQ: 298380)) in combination with Bristol Myers Squibb's immune checkpoint inhibitor nivolumab.
Express News | I-Mab: Collaboration With Bristol Myers to Evaluate Claudin 18.2 X 4-1Bb Bispecific Antibody Givastomig in Combination With Nivolumab and Chemotherapy
Express News | I-Mab Announces Collaboration With Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersConcord Medical Services (NYSE:CCM) shares moved upwards by 51.9% to $1.2 during Tuesday's regular session. The market value of their outstanding shares is at $52.1 million. Annexon (NASDAQ:ANN
I-Mab's Ragistomig Shows Promise in Phase 1 Trials
Express News | I-Mab: Encouraging Objective Responses Were Observed in Heavily Pre-Treated Patients in Study
Express News | I-Mab: Phase 1 Dose-Escalation Data Demonstrated That Ragistomig Monotherapy Can Be Safely Administered Through Highest Planned Doses
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
I-Mab (NASDAQ: IMAB) today announced that Gerald Falchook, MD, and the team at I-Mab's partner for ragistomig (or "ABL503"), ABL Bio (KOSDAQ: 298380), will present a poster related to Phase 1 data for ragistomig at the 2024 American Society for Clinical Oncology Annual Meeting ("ASCO 2024"), taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL.
I-Mab to Participate at the Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated
(IMAB) - Analyzing I-MAB's Short Interest
I-MAB's (NYSE:IMAB) short percent of float has risen 113.98% since its last report. The company recently reported that it has 1.30 million shares sold short, which is 3.98% of all regular shares that
Patent Law Changes Pose Threat to I-Mab Adr's Drug Candidate Protection
I-MAB Filed 2023 Annual Report on Form 20-F
ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hig
Verastem Names John Hayslip as Chief Medical Officer
Verastem (VSTM) said late Thursday it appointed John Hayslip as chief medical officer, succeeding Louis Denis, who recently left the company. Hayslip most recently served as the chief medical officer
No Data